Anteris Technologies Global Corp. AVR 深 沪
等待开盘 12-19 09:30:00 美东时间
5.47
+0.730
+15.40%
华盛通- 最 高5.8299
- 今 开5.08
- 成交量 54.04万股
- 最 低 5.01
- 昨 收 4.74
- 总市值 2.25亿
- 52周最高 8.79
- 市盈率 静 --
- 换手率 1.31%
- 52周最低 2.34
- 委 比 -61.47%
- 总股本 4119.76万
- 历史最高 8.79
- 量 比 2.83
- 振 幅 17.30%
- 历史最低 2.34
- 每 手 1
- 风险率 1.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Athira Pharma (NASDAQ:ATHA) stock rose 70.0% to $7.03 during Thursday'...
今天 01:06
Stephen Denaro Resigns from Anteris Board
Anteris Technologies Global Corp. ( ($AVR) ) just unveiled an update. On Decemb...
12-15 19:29
Anteris Technologies Issues Restricted Stock Units
Anteris Technologies ( ($AU:AVR) ) has shared an update. Anteris Technologies G...
12-12 14:18
Anteris Technologies Global To Offer Up To 9.1M Shares Of Common Stock By The Selling Stockholders
- SEC Filing
11-27 05:40
Anteris Technologies Reports Q3 2025 Progress and Financials
Anteris Technologies Global Corp. ( ($AVR) ) has released its Q3 earnings. Here...
11-24 11:50
Anteris Highlights 100% Technical Success In Last 50 DurAVR THV Implants And No Valve Related Mortality At 30 Days
30-day Results Highlights for 100 DurAVR THV PatientsDurAVR THV delivered a favorable hemodynamic profile with a large EOA of 2.2 ± 0.3 cm2 and a single digit mean pressure gradient (MPG) of 8.2 ± 3.1
11-17 19:04
Anteris Announces Results for the Third Quarter of 2025
Anteris reported Q3 2025 financial results, highlighting FDA and European approvals for the PARADIGM Trial, patient recruitment progress, operational readiness enhancements, and $59.3 million net cash outflow. Key focus areas included regulatory advancement, clinical trial preparation, and manufacturing scale-up.
11-12 22:52
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
Anteris Technologies Global Corp. announced one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) in patients with symptomatic severe aortic stenosis and small aortic annuli. The DurAVR® system demonstrated favorable hemodynamics, including an effective orifice area (EOA) of 2.1 ± 0.2 cm² and a mean pressure gradient (MPG) of 8.6 ± 2.6 mmHg, with no moderate or severe paravalvular leaks or valve-related mortality. At 30 days,...
10-28 22:08
Anteris Technologies Requests Voluntary Suspension of Securities
The latest update is out from Anteris Technologies ( ($AU:AVR) ). Anteris Techn...
10-28 10:18
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Anteris Technologies Global Corp. announced the initiation of the PARADIGM Trial, a global pivotal study evaluating the DurAVR® Transcatheter Heart Valve (THV) for patients with severe calcific aortic stenosis. The first patients have been enrolled and successfully treated in this trial, conducted by Prof. Dr. Ole De Backer at Copenhagen University Hospital. The PARADIGM Trial aims to compare the safety and efficacy of DurAVR® THV with commercial...
10-27 21:43
